- Home
- LNW vs EXEL Comparison
LNW vs EXEL Comparison
Compare LNW & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNW
- EXEL
- Stock Information
- Founded
- LNW 1984
- EXEL 1994
- Country
- LNW United States
- EXEL United States
- Employees
- LNW N/A
- EXEL N/A
- Industry
- LNW EDP Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LNW Technology
- EXEL Health Care
- Exchange
- LNW Nasdaq
- EXEL Nasdaq
- Market Cap
- LNW 9.0B
- EXEL 9.4B
- IPO Year
- LNW N/A
- EXEL 2000
- Fundamental
- Price
- LNW $101.83
- EXEL $36.85
- Analyst Decision
- LNW Buy
- EXEL Buy
- Analyst Count
- LNW 12
- EXEL 18
- Target Price
- LNW $109.25
- EXEL $37.24
- AVG Volume (30 Days)
- LNW 751.7K
- EXEL 2.6M
- Earning Date
- LNW 02-25-2025
- EXEL 02-11-2025
- Dividend Yield
- LNW N/A
- EXEL N/A
- EPS Growth
- LNW 141.51
- EXEL 170.77
- EPS
- LNW 3.21
- EXEL 1.76
- Revenue
- LNW $3,162,000,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- LNW $10.79
- EXEL $5.36
- Revenue Next Year
- LNW $6.97
- EXEL $10.59
- P/E Ratio
- LNW $31.73
- EXEL $20.94
- Revenue Growth
- LNW 12.41
- EXEL 18.49
- 52 Week Low
- LNW $84.00
- EXEL $20.14
- 52 Week High
- LNW $115.00
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- LNW 64.77
- EXEL 65.59
- Support Level
- LNW $93.47
- EXEL $34.01
- Resistance Level
- LNW $106.95
- EXEL $35.46
- Average True Range (ATR)
- LNW 2.88
- EXEL 1.09
- MACD
- LNW 1.50
- EXEL 0.36
- Stochastic Oscillator
- LNW 77.09
- EXEL 95.70
About LNW Light & Wonder Inc.
Light & Wonder is principally an electronic gaming machine manufacturer, selling machines to pubs, clubs, and casinos. The firm is licensed in most jurisdictions allowing gambling globally. Light & Wonder is one of the three largest players in the space along with International Game Technology and Aristocrat Leisure. SciPlay, about one fourth of revenue, develops and distributes casual mobile games, principally in the social casino niche. The more nascent iGaming business sits between these two businesses, providing digital content and capabilities to real-money gaming providers.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.